MedTrace Logo

MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043)

NCT00371007 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2017-04-04

No results posted yet for this study

Summary

A clinical study to determine the safety and efficacy of MK-0431 in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy

Conditions

Interventions

DRUG

MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks

DRUG

Comparator : placebo (unspecified) / Duration of Treatment: 12 Weeks

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-01
Primary Completion
2005-04-25
Completion
2005-04-25

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00371007 on ClinicalTrials.gov